Free Trial
NASDAQ:VIGL

Vigil Neuroscience Q4 2024 Earnings Report

Vigil Neuroscience logo
$8.05 0.00 (0.00%)
As of 08/5/2025

Vigil Neuroscience EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Vigil Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vigil Neuroscience Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Vigil Neuroscience's Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

Vigil Neuroscience Earnings Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
See More Vigil Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vigil Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vigil Neuroscience and other key companies, straight to your email.

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL), a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

View Vigil Neuroscience Profile

More Earnings Resources from MarketBeat